Researchers found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer who took the combination therapy ribociclib, a targeted therapy drug, and hormone therapy had substantially longer invasive disease-free survival compared to those who were treated with the hormone therapy alone.This